According to extensive research conducted by Growth Plus Reports, the market for influenza diagnostics was estimated to be around US$ 1.1 billion in 2022 and is expected to expand at a 3.7% revenue CAGR with a market value of US$ 1.52 billion by 2031.
The influenza virus causes influenza, most frequently referred to as the flu. The virus can cause mild to severe disease and, in extreme circumstances, death by infecting the nose, throat, and lungs. The term "influenza diagnostics" describes the procedures and equipment used to determine whether the virus is present in a person's body.
Influenza diagnostics includes various diagnostic methods, devices, and assays designed to identify the presence of influenza viruses and distinguish between different influenza strains.
What are the major drivers for the influenza diagnostics market?
Which are the top companies for Influenza diagnostics?
Which segment dominates the global influenza diagnostics market?
In 2022, the conventional diagnostic test category held most of the market's revenue. The rapid influenza diagnostic test (RIDT), viral culture, direct fluorescent antibody (DFA) test, and serological assay are some of the methods of influenza diagnosis included in the conventional diagnostic test that has been in use for a long time. A diagnostic test known as the rapid influenza diagnostic test (RIDT) is used to find viral antigens in respiratory specimens like nose or throat swabs.